Developing Recovery Care Services for Post-ASC Care
"The challenge is, we all know the quality of care we can provide in our ASCs," Mr. Newman said. "However, these patients for total knee or total hip, they're going to require some more significant recovery care than we can provide within the ambulatory care environment."
Recovery care services provide a number of opportunities, such as benefits for the patients. Additionally, such services can help recruit physicians, Mr. Newman said. For example, if an ASC provides a recovery care service, patients can come to the ASC for more complex procedures, attracting new physicians. "[Physicians] may be willing to migrate some of their activity to your center," he said.
When looking to develop such recovery care services, Mr. Newman said it is important to check state-by-state regulations, as each state may require different licensing and statues.
"What you need to do is dialogue with your counsel and with state regulators to determine what are the requirements and what are the options for providing rehabilitative care," Mr. Newman said.
Overall, the providing recovery care centers and services can be highly beneficial.
"There's just a terrific opportunity here that you really shouldn't miss because this is something that is coming to the market," Mr. Newman said. "To not address it will put you behind rather than ahead of the game."
More Articles on Turnarounds:
8 Business Considerations for Starting an Independent Practice
To Save, Take Back the Supply Chain With Generics, Tracking
10 ASCs Making the News This Week
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- Drug-resistant tuberculosis alarms health officials — 4 notes
- Preventing & combating healthcare fraud: An ongoing process for ASCs
- Dr. Thomas Frieden talks opioids, antibiotic resistance & more with MedPage Today during final days at CDC
- Orphan drugs' annual average price tag cost $88.4k more than mainstream drugs in 2014: 4 key statistics
- GI leader to know: Dr. Robert Levine of the Boulder Medical Center